Effective Treatments for Bladder Cancer Affecting CXCL9/CXCL10/CXCL11/ CXCR3 Axis: A Review
Open Access
- 11 March 2020
- journal article
- review article
- Published by Oman Medical Journal in Oman Medical Journal
- Vol. 35 (2), e103
- https://doi.org/10.5001/omj.2020.21
Abstract
Bladder cancer (BC) originates mainly from the epithelial compartment of the bladder, which is defined as transitional cell carcinoma or urothelial cell carcinoma. About 70% of patients with BC will survive five years from diagnosis. Previous studies revealed that the immune system and its mediators, particularly chemokines, play a crucial role in modulating responses against BC. Chemokines, which serve as chemoattractants for leukocytes, are small proteins that can initiate inflammatory and anti-inflammatory immune responses and also are associated with many aspects of both regulation and progression of mentioned responses. Additionally, these immune mediators can interfere with the other tumor-related processes, including tumor proliferation, neovascularization, and metastases. Among these chemokines, CXC chemokines, including CXCL9, CXCL10, and CXCL11, are recognized as the main ligands of C-X-C motif chemokine receptor 3 (CXCR3) and contribute to related immune responses after therapeutic strategies for BC. Evidence suggests that the production of these chemokines can have two important implications. First, these mediators can trigger the accumulation of CD8+ T cells that can contribute to the elimination of the tumor. Secondly, the production of these chemokines by tumor tissue may trigger the migration and activation of immune cells including myeloid-derived suppressor cells and regulatory T cells, which act in favor of the tumor and its progress. Therefore, in this review, we describe the latest therapeutic approaches based on targeting this axis's components and subsequent immune phenomenon.Keywords
This publication has 100 references indexed in Scilit:
- Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasionMolecular Cancer, 2012
- Discrimination of agonist and antagonist forms of CXCL10 in biological samplesClinical and Experimental Immunology, 2011
- Atypical chemokine receptorsExperimental Cell Research, 2011
- CXCR3-B Can Mediate Growth-inhibitory Signals in Human Renal Cancer Cells by Down-regulating the Expression of Heme Oxygenase-1Online Journal of Public Health Informatics, 2010
- CXC Chemokines in Cancer Angiogenesis and MetastasesAdvances in Cancer Research, 2010
- The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammationNature Immunology, 2009
- The tumor microenvironment and its role in promoting tumor growthOncogene, 2008
- Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette–Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladderImmunology, 2008
- Inhibition of Gαi2 Activation by Gαi3 in CXCR3-mediated SignalingOnline Journal of Public Health Informatics, 2007
- Mycobacterium bovis bacillus Calmette–Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivoClinical and Experimental Immunology, 2006